Eli Lilly and Company: Carcinoma, Renal Cell trials
The registry lists 10 Carcinoma, Renal Cell studies with Eli Lilly and Company as lead sponsor. 0 are open to participants now and 8 have results posted.
Phase 1 6Phase 2 4No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced CancerCompletedNCT04148937Phase 1Results posted
- A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced CancerCompletedNCT02082210Phase 1/2Results posted
- A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid TumorsCompletedNCT02009449Phase 1Results posted
- Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis CarcinomaCompletedNCT01282463Phase 2Results posted
- A Phase 1b Trial in Patients With Renal Cell CancerCompletedNCT01258348Phase 1Results posted
- A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid TumorsTerminatedNCT01115803Phase 1Results posted
- A Study for Participants With Metastatic Renal Cell CarcinomaCompletedNCT00709995Phase 2Results posted
- A Study of Ramucirumab in Participants With Metastatic Renal Cell CarcinomaCompletedNCT00515697Phase 2Results posted
- An Expanded Access Program for AM0010 (Pegilodecakin)No longer availableNCT03554434
- A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid TumorsTerminatedNCT03343613Phase 1